Cargando…
A Fully Human Monoclonal Antibody Targeting cKIT Is a Potent Inhibitor of Pathological Choroidal Neovascularization in Mice
Stem cell factor (SCF) and its receptor, cKIT, are novel regulators of pathological neovascularization in the eye, which suggests that inhibition of SCF/cKIT signaling may be a novel pharmacological strategy for treating neovascular age-related macular degeneration (AMD). This study evaluated the th...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8400730/ https://www.ncbi.nlm.nih.gov/pubmed/34452268 http://dx.doi.org/10.3390/pharmaceutics13081308 |
_version_ | 1783745384155185152 |
---|---|
author | Seo, Songyi Kim, Koung Li Yeo, Yeongju Kim, Ryul-I Jeong, Hayoung Kim, Jin-Ock Song, Sun-Hwa An, Mi-Jin Kim, Jung-Woong Hong, Hye Kyoung Ham, Min Hee Woo, Se Joon Sung, Jong-Hyuk Park, Sang Gyu Suh, Wonhee |
author_facet | Seo, Songyi Kim, Koung Li Yeo, Yeongju Kim, Ryul-I Jeong, Hayoung Kim, Jin-Ock Song, Sun-Hwa An, Mi-Jin Kim, Jung-Woong Hong, Hye Kyoung Ham, Min Hee Woo, Se Joon Sung, Jong-Hyuk Park, Sang Gyu Suh, Wonhee |
author_sort | Seo, Songyi |
collection | PubMed |
description | Stem cell factor (SCF) and its receptor, cKIT, are novel regulators of pathological neovascularization in the eye, which suggests that inhibition of SCF/cKIT signaling may be a novel pharmacological strategy for treating neovascular age-related macular degeneration (AMD). This study evaluated the therapeutic potential of a newly developed fully human monoclonal antibody targeting cKIT, NN2101, in a murine model of neovascular AMD. In hypoxic human endothelial cells, NN2101 substantially inhibited the SCF-induced increase in angiogenesis and activation of the cKIT signaling pathway. In a murine model of neovascular AMD, intravitreal injection of NN2101 substantially inhibited the SCF/cKIT-mediated choroidal neovascularization (CNV), with efficacy comparable to aflibercept, a vascular endothelial growth factor inhibitor. A combined intravitreal injection of NN2101 and aflibercept resulted in an additive therapeutic effect on CNV. NN2101 neither caused ocular toxicity nor interfered with the early retinal vascular development in mice. Ocular pharmacokinetic analysis in rabbits indicated that NN2101 demonstrated a pharmacokinetic profile suitable for intravitreal injection. These findings provide the first evidence of the potential use of the anti-cKIT blocking antibody, NN2101, as an alternative or additive therapeutic for the treatment of neovascular AMD. |
format | Online Article Text |
id | pubmed-8400730 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-84007302021-08-29 A Fully Human Monoclonal Antibody Targeting cKIT Is a Potent Inhibitor of Pathological Choroidal Neovascularization in Mice Seo, Songyi Kim, Koung Li Yeo, Yeongju Kim, Ryul-I Jeong, Hayoung Kim, Jin-Ock Song, Sun-Hwa An, Mi-Jin Kim, Jung-Woong Hong, Hye Kyoung Ham, Min Hee Woo, Se Joon Sung, Jong-Hyuk Park, Sang Gyu Suh, Wonhee Pharmaceutics Article Stem cell factor (SCF) and its receptor, cKIT, are novel regulators of pathological neovascularization in the eye, which suggests that inhibition of SCF/cKIT signaling may be a novel pharmacological strategy for treating neovascular age-related macular degeneration (AMD). This study evaluated the therapeutic potential of a newly developed fully human monoclonal antibody targeting cKIT, NN2101, in a murine model of neovascular AMD. In hypoxic human endothelial cells, NN2101 substantially inhibited the SCF-induced increase in angiogenesis and activation of the cKIT signaling pathway. In a murine model of neovascular AMD, intravitreal injection of NN2101 substantially inhibited the SCF/cKIT-mediated choroidal neovascularization (CNV), with efficacy comparable to aflibercept, a vascular endothelial growth factor inhibitor. A combined intravitreal injection of NN2101 and aflibercept resulted in an additive therapeutic effect on CNV. NN2101 neither caused ocular toxicity nor interfered with the early retinal vascular development in mice. Ocular pharmacokinetic analysis in rabbits indicated that NN2101 demonstrated a pharmacokinetic profile suitable for intravitreal injection. These findings provide the first evidence of the potential use of the anti-cKIT blocking antibody, NN2101, as an alternative or additive therapeutic for the treatment of neovascular AMD. MDPI 2021-08-20 /pmc/articles/PMC8400730/ /pubmed/34452268 http://dx.doi.org/10.3390/pharmaceutics13081308 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Seo, Songyi Kim, Koung Li Yeo, Yeongju Kim, Ryul-I Jeong, Hayoung Kim, Jin-Ock Song, Sun-Hwa An, Mi-Jin Kim, Jung-Woong Hong, Hye Kyoung Ham, Min Hee Woo, Se Joon Sung, Jong-Hyuk Park, Sang Gyu Suh, Wonhee A Fully Human Monoclonal Antibody Targeting cKIT Is a Potent Inhibitor of Pathological Choroidal Neovascularization in Mice |
title | A Fully Human Monoclonal Antibody Targeting cKIT Is a Potent Inhibitor of Pathological Choroidal Neovascularization in Mice |
title_full | A Fully Human Monoclonal Antibody Targeting cKIT Is a Potent Inhibitor of Pathological Choroidal Neovascularization in Mice |
title_fullStr | A Fully Human Monoclonal Antibody Targeting cKIT Is a Potent Inhibitor of Pathological Choroidal Neovascularization in Mice |
title_full_unstemmed | A Fully Human Monoclonal Antibody Targeting cKIT Is a Potent Inhibitor of Pathological Choroidal Neovascularization in Mice |
title_short | A Fully Human Monoclonal Antibody Targeting cKIT Is a Potent Inhibitor of Pathological Choroidal Neovascularization in Mice |
title_sort | fully human monoclonal antibody targeting ckit is a potent inhibitor of pathological choroidal neovascularization in mice |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8400730/ https://www.ncbi.nlm.nih.gov/pubmed/34452268 http://dx.doi.org/10.3390/pharmaceutics13081308 |
work_keys_str_mv | AT seosongyi afullyhumanmonoclonalantibodytargetingckitisapotentinhibitorofpathologicalchoroidalneovascularizationinmice AT kimkoungli afullyhumanmonoclonalantibodytargetingckitisapotentinhibitorofpathologicalchoroidalneovascularizationinmice AT yeoyeongju afullyhumanmonoclonalantibodytargetingckitisapotentinhibitorofpathologicalchoroidalneovascularizationinmice AT kimryuli afullyhumanmonoclonalantibodytargetingckitisapotentinhibitorofpathologicalchoroidalneovascularizationinmice AT jeonghayoung afullyhumanmonoclonalantibodytargetingckitisapotentinhibitorofpathologicalchoroidalneovascularizationinmice AT kimjinock afullyhumanmonoclonalantibodytargetingckitisapotentinhibitorofpathologicalchoroidalneovascularizationinmice AT songsunhwa afullyhumanmonoclonalantibodytargetingckitisapotentinhibitorofpathologicalchoroidalneovascularizationinmice AT anmijin afullyhumanmonoclonalantibodytargetingckitisapotentinhibitorofpathologicalchoroidalneovascularizationinmice AT kimjungwoong afullyhumanmonoclonalantibodytargetingckitisapotentinhibitorofpathologicalchoroidalneovascularizationinmice AT honghyekyoung afullyhumanmonoclonalantibodytargetingckitisapotentinhibitorofpathologicalchoroidalneovascularizationinmice AT hamminhee afullyhumanmonoclonalantibodytargetingckitisapotentinhibitorofpathologicalchoroidalneovascularizationinmice AT woosejoon afullyhumanmonoclonalantibodytargetingckitisapotentinhibitorofpathologicalchoroidalneovascularizationinmice AT sungjonghyuk afullyhumanmonoclonalantibodytargetingckitisapotentinhibitorofpathologicalchoroidalneovascularizationinmice AT parksanggyu afullyhumanmonoclonalantibodytargetingckitisapotentinhibitorofpathologicalchoroidalneovascularizationinmice AT suhwonhee afullyhumanmonoclonalantibodytargetingckitisapotentinhibitorofpathologicalchoroidalneovascularizationinmice AT seosongyi fullyhumanmonoclonalantibodytargetingckitisapotentinhibitorofpathologicalchoroidalneovascularizationinmice AT kimkoungli fullyhumanmonoclonalantibodytargetingckitisapotentinhibitorofpathologicalchoroidalneovascularizationinmice AT yeoyeongju fullyhumanmonoclonalantibodytargetingckitisapotentinhibitorofpathologicalchoroidalneovascularizationinmice AT kimryuli fullyhumanmonoclonalantibodytargetingckitisapotentinhibitorofpathologicalchoroidalneovascularizationinmice AT jeonghayoung fullyhumanmonoclonalantibodytargetingckitisapotentinhibitorofpathologicalchoroidalneovascularizationinmice AT kimjinock fullyhumanmonoclonalantibodytargetingckitisapotentinhibitorofpathologicalchoroidalneovascularizationinmice AT songsunhwa fullyhumanmonoclonalantibodytargetingckitisapotentinhibitorofpathologicalchoroidalneovascularizationinmice AT anmijin fullyhumanmonoclonalantibodytargetingckitisapotentinhibitorofpathologicalchoroidalneovascularizationinmice AT kimjungwoong fullyhumanmonoclonalantibodytargetingckitisapotentinhibitorofpathologicalchoroidalneovascularizationinmice AT honghyekyoung fullyhumanmonoclonalantibodytargetingckitisapotentinhibitorofpathologicalchoroidalneovascularizationinmice AT hamminhee fullyhumanmonoclonalantibodytargetingckitisapotentinhibitorofpathologicalchoroidalneovascularizationinmice AT woosejoon fullyhumanmonoclonalantibodytargetingckitisapotentinhibitorofpathologicalchoroidalneovascularizationinmice AT sungjonghyuk fullyhumanmonoclonalantibodytargetingckitisapotentinhibitorofpathologicalchoroidalneovascularizationinmice AT parksanggyu fullyhumanmonoclonalantibodytargetingckitisapotentinhibitorofpathologicalchoroidalneovascularizationinmice AT suhwonhee fullyhumanmonoclonalantibodytargetingckitisapotentinhibitorofpathologicalchoroidalneovascularizationinmice |